Startups
Discover Cyclomics, pioneers in precision cancer diagnostics using breakthrough consensus-sequencing paired with the Nanopore platform. Our innovative solutions enable ultra-sensitive detection of cancer mutations directly from blood samples, transforming the future of liquid biopsy. Learn more about how Cyclomics is revolutionizing early cancer detection, monitoring, and personalized treatment with cutting-edge, accessible molecular diagnostics.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 16, 2024 | Blood Genetic Testing Using Nvidia AI Chips; Emerging from Cyclomics Acquisition for Renovaro: Nasdaq: RENB: | GediCube Renovaro Biosciences NASDAQ; RENB NASDAQ: $RENB $RENB AI Healthcare $RENB Strategic Partners Transforming Cancer Diagnosis: Renovaro Biosciences (Nasdaq: RENB) Introduces Cutting-Edge Blood Genetic Testing Powered by Nvidia AI Chip... |
| Dec 20, 2023 | Transforming Cancer Care: The Future of Faster, Reliable Diagnostics in Healthcare? | Key Takeaways: Cyclomics is a Dutch startup seeking to revolutionalize cancer care by enhancing the speed and reliability of diagnoses, particularly in the context of cancer recurrence. Cyclomics’ proprietary circulating tumor DNA (ctDNA) d... |
| Cyclomics | “Discover Cyclomics, pioneers in precision cancer diagnostics using breakthrough consensus-sequencing paired with the Nanopore platform. Our innovative solutions enable ultra-sensitive detection of cancer mutations directly from blood sampl... |
Reviews 0
FAQ about Cyclomics
What has the press written about Cyclomics?
Parsers VC has collected 4 articles mentioning Cyclomics, among them “Blood Genetic Testing Using Nvidia AI Chips; Emerging from Cyclomics Acquisition for Renovaro: Nasdaq: RENB:” (Feb 16, 2024) and “Transforming Cancer Care: The Future of Faster, Reliable Diagnostics in Healthcare?” (Dec 20, 2023).
Is Cyclomics still active?
Yes, Cyclomics is active; its latest activity on Parsers VC dates from Feb 22, 2024.